Menu
Search
|

Menu

Close
X

Mirati Therapeutics Inc MRTX.OQ (NASDAQ Stock Exchange Global Select Market)

75.63 USD
+0.09 (+0.12%)
As of 4:32 PM GMT
chart
Previous Close 75.54
Open 75.33
Volume 71,696
3m Avg Volume 233,621
Today’s High 75.70
Today’s Low 71.72
52 Week High 76.00
52 Week Low 24.65
Shares Outstanding (mil) 24.97
Market Capitalization (mil) 362.06
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.75 Mean rating from 12 analysts

KEY STATS

Revenue (mm, USD)
FY18
9
FY17
0
FY16
0
EPS (USD)
FY18
-2.297
FY17
-2.788
FY16
-4.203
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.70
Price to Sales (TTM)
vs sector
--
6.29
Price to Book (MRQ)
vs sector
4.36
5.26
Price to Cash Flow (TTM)
vs sector
--
24.98
Total Debt to Equity (MRQ)
vs sector
0.00
16.12
LT Debt to Equity (MRQ)
vs sector
0.00
11.38
Return on Investment (TTM)
vs sector
-91.06
14.45
Return on Equity (TTM)
vs sector
-91.23
15.96

EXECUTIVE LEADERSHIP

Faheem Hasnain
Chairman of the Board, Since 2019
Salary: --
Bonus: --
Charles Baum
President, Chief Executive Officer, Director, Since 2012
Salary: $562,800.00
Bonus: --
Jamie Donadio
Chief Financial Officer, Senior Vice President, Since 2016
Salary: --
Bonus: --
Isan Chen
Chief Medical and Development Officer, Executive Vice President, Since 2013
Salary: $408,300.00
Bonus: --
Christopher LeMasters
Executive Vice President, Chief Business Officer, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

9393 Towne Centre Dr Ste 200
SAN DIEGO   CA   92121-3070

Phone: +1858.3323410

Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company's clinical pipeline consists of three product candidates: MGCD265, MGCD516 and mocetinostat. MGCD265 and MGCD516 are orally-bioavailable, spectrum-selective kinase inhibitors. Both MGCD265 and MGCD516 are in development to treat patients with non-small cell lung cancer (NSCLC), and other solid tumors. MGCD265 is in Phase Ib clinical development and MGCD516 is in the dose escalation phase of Phase I clinical development. Mocetinostat is an orally-bioavailable, spectrum-selective histone deacetylase (HDAC), inhibitor, which is in Phase II development. Mocetinostat is being developed for the second line treatment of patients with bladder cancer and non-hodgkins lymphoma (NHL), specifically focusing on diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL).

SPONSORED STORIES